The next of several Risperdal breast growth lawsuits will begin on May 26th in a Philadelphia court. Drug manufacturer Janssen Pharmaceuticals and parent company Johnson & Johnson have faced multiple lawsuits alleging that the antipsychotic drug caused boys and male adolescents to develop breasts, a condition known as gynecomastia.
Janssen recently paid millions to a 20-year old man who began taking Risperdal at age 12 before developing size 44 DD breasts. The drug has been linked to an increased risk of elevated levels of prolactin, the hormone responsible for breast tissue growth.
Janssen and J&J could face hundreds of Risperdal lawsuits alleging similar side effects from boys and young men who were given the drug to treat various conditions, such as bipolar disorder or symptoms related to ADHD. The company has also recently settled several lawsuits alleging that it illegally promoted the drug for unapproved uses, including the treatment of ADHD.